| Business Summary | | AstraZeneca
PLC
is
a
pharmaceutical
company
that
provides
products
to
fight
disease
in
important
areas
of
medical
need.
The
Company
focuses
on
seven
major
therapeutic
areas:
cancer
(oncology);
cardiovascular;
central
nervous
system;
gastrointestinal;
infection;
pain
control
and
anesthesia,
and
respiratory.
The
Company's
non-pharmaceutical
businesses
include
Astra
Tech,
Salick
Health
Care,
Inc.
(SHC)
and
Cellmark
Diagnostics.
Astra
Tech
develops
and
markets
advanced
medical
devices
and
implants,
focusing
primarily
on
urology,
surgery,
dental
implants
and
diagnostic
imaging.
SHC
provides
a
broad
range
of
services
to
health
insurers,
oncologists,
other
specialists
and
their
patients
in
the
United
States,
principally
in
the
diagnosis
and
treatment
of
cancer
and
the
treatment
of
kidney
failure.
Cellmark
Diagnostics
is
engaged
in
DNA
fingerprinting
outside
the
United
States. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | AstraZeneca
PLC
is
an
international
biosciences
company
engaged
in
the
R&D,
manufacture
and
marketing
of
ethical
pharmaceuticals,
agricultural
and
specialty
chemicals
products,
and
the
supply
of
healthcare
services.
For
the
three
months
ended
3/31/01,
revenues
rose
3%
to
$3.99
billion.
Net
income
rose
18%
to
$782
million.
Revenues
reflect
increased
Cardiovascular
and
Respiratory
sales.
Earnings
also
reflect
higher
margins
and
increased
interest
and
dividend
income. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
4,099;
after
tax
earnings
were
1,019. (Preliminary; reported in millions of dollars.) | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Percy Barnevik | Non-Exec.
Chairman | Tom McKillop | CEO | Jonathan Symonds | CFO,
Director | Barrie Thorpe | VP-
Operations | Luk Vranken | VP
of Sales and Marketing |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|